AVL 292 - CC 292 | Spebrutinib

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 2226

CAS [1202757-89-8]

MF C22H22FN5O3
MW 423.44

  • Purity: 98%
  • Soluble in DMSO

AVL 292


A potent, selective, orally bioavailable, covalent Bruton's tyrosine kinase (Btk) inhibitor with potential antineoplastic activity (IC50 value 1400 selective over a number of Src family kinases and B cell signaling components in full length recombinant Btk protein assay). More specific for BTK than PCI 32765 (Ibrutinib, Axon 1858) is, and with a shorter half-life.
AVL 292 reduces migration of CLL cells towards CXCL12 and CXCL13, and reduces viability as well as markers of BCR activation, such as CCL3 and CCL4 chemokine production, in primary CLL cells cultured with Nurse-like Cells (NLC).

Size Unit Price Stock
5 mg €110.00 In Stock
25 mg €330.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €160.00 In Stock
2 x 25 mg €500.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...